New Insight into the Molecular Drug Target of Diabetic Nephropathy

Diabetic nephropathy (DN) lowered quality of life and shortened life expectancy amongst those affected. Evidence indicates interaction between advanced glycation end products (AGEs), activated protein kinase C (PKC) and angiotensin II exacerbate the progression of DN. Inhibitors of angiotensin-conv...

Full description

Saved in:
Bibliographic Details
Main Authors: Vivian Soetikno, Wawaimuli Arozal, Melva Louisa, Rianto Setiabudy
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2014/968681
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850222384452206592
author Vivian Soetikno
Wawaimuli Arozal
Melva Louisa
Rianto Setiabudy
author_facet Vivian Soetikno
Wawaimuli Arozal
Melva Louisa
Rianto Setiabudy
author_sort Vivian Soetikno
collection DOAJ
description Diabetic nephropathy (DN) lowered quality of life and shortened life expectancy amongst those affected. Evidence indicates interaction between advanced glycation end products (AGEs), activated protein kinase C (PKC) and angiotensin II exacerbate the progression of DN. Inhibitors of angiotensin-converting enzyme (ACEIs), renin angiotensin aldosterone system (RAAS), AGEs, and PKC have been tested for slowing down the progression of DN. The exact molecular drug targets that lead to the amelioration of renal injury in DN are not well understood. This review summarizes the potential therapeutic targets, based on putative mechanism in the progression of the disease.
format Article
id doaj-art-6f7acd61f8ed48949084e0366ffd64fb
institution OA Journals
issn 1687-8337
1687-8345
language English
publishDate 2014-01-01
publisher Wiley
record_format Article
series International Journal of Endocrinology
spelling doaj-art-6f7acd61f8ed48949084e0366ffd64fb2025-08-20T02:06:22ZengWileyInternational Journal of Endocrinology1687-83371687-83452014-01-01201410.1155/2014/968681968681New Insight into the Molecular Drug Target of Diabetic NephropathyVivian Soetikno0Wawaimuli Arozal1Melva Louisa2Rianto Setiabudy3Department of Pharmacology and Therapeutic, Faculty of Medicine, University of Indonesia, Salemba Raya 6, Jakarta 10430, IndonesiaDepartment of Pharmacology and Therapeutic, Faculty of Medicine, University of Indonesia, Salemba Raya 6, Jakarta 10430, IndonesiaDepartment of Pharmacology and Therapeutic, Faculty of Medicine, University of Indonesia, Salemba Raya 6, Jakarta 10430, IndonesiaDepartment of Pharmacology and Therapeutic, Faculty of Medicine, University of Indonesia, Salemba Raya 6, Jakarta 10430, IndonesiaDiabetic nephropathy (DN) lowered quality of life and shortened life expectancy amongst those affected. Evidence indicates interaction between advanced glycation end products (AGEs), activated protein kinase C (PKC) and angiotensin II exacerbate the progression of DN. Inhibitors of angiotensin-converting enzyme (ACEIs), renin angiotensin aldosterone system (RAAS), AGEs, and PKC have been tested for slowing down the progression of DN. The exact molecular drug targets that lead to the amelioration of renal injury in DN are not well understood. This review summarizes the potential therapeutic targets, based on putative mechanism in the progression of the disease.http://dx.doi.org/10.1155/2014/968681
spellingShingle Vivian Soetikno
Wawaimuli Arozal
Melva Louisa
Rianto Setiabudy
New Insight into the Molecular Drug Target of Diabetic Nephropathy
International Journal of Endocrinology
title New Insight into the Molecular Drug Target of Diabetic Nephropathy
title_full New Insight into the Molecular Drug Target of Diabetic Nephropathy
title_fullStr New Insight into the Molecular Drug Target of Diabetic Nephropathy
title_full_unstemmed New Insight into the Molecular Drug Target of Diabetic Nephropathy
title_short New Insight into the Molecular Drug Target of Diabetic Nephropathy
title_sort new insight into the molecular drug target of diabetic nephropathy
url http://dx.doi.org/10.1155/2014/968681
work_keys_str_mv AT viviansoetikno newinsightintothemoleculardrugtargetofdiabeticnephropathy
AT wawaimuliarozal newinsightintothemoleculardrugtargetofdiabeticnephropathy
AT melvalouisa newinsightintothemoleculardrugtargetofdiabeticnephropathy
AT riantosetiabudy newinsightintothemoleculardrugtargetofdiabeticnephropathy